Loading quotes...

Forecast

Buy	6
Hold	2
Sell	0

News Go to news feed

Lifeward shareholders approve partnership with Oramed and potential capital injection

Lifeward has approved the issuance of common shares as part of a strategic partnership with Oramed, potentially giving the company access to up to about $47 million from Oramed and an additional investor. The financing includes equity, convertible bonds, milestone payments and warrants. Oramed will manage and fund the clinical development program for the POD technology, which aims to enable oral delivery of biopharmaceuticals, while Lifeward will focus on its medical technology business. Lifeward shares jumped more than 10% after the announcement but remain down around 65% year-to-date; completion of the transaction is still subject to customary conditions. » More on de.investing.com
Oramed receives $18 million from Scilex and announces cash dividend

Oramed has received a payment of $18 million from Scilex, fulfilling all obligations under an option agreement and raising the total return on the original $99.5 million investment to $118 million. Oramed also retains a $27 million promissory note, a $12 million convertible note (conversion price $36 per share), warrants and a nine‑year royalty/license interest in Scilex products. The board approved a cash dividend of $0.25 per share (ex‑date January 16, 2026; payment January 26, 2026), to be financed from surplus funds; the share price then rose by about 6.2%. » More on de.investing.com
Oramed Pharmaceuticals: Leonard Sank steps down from director post after 18 years

Leonard Sank has announced he will resign his mandate on the supervisory board of Oramed Pharmaceuticals effective January 1, 2026. The company emphasizes that his resignation is not due to disagreements over management, policies, or practices. Sank served 18 years as a director. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Oramed Pharmaceuticals has already paid €0.21 in dividends. The last payout was in January.

Financials

In the last quarter, Oramed Pharmaceuticals had revenue of €0 and net profit of €68.48m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	68.48m	507.43%
EBITDA	89.04m	697.22%

Fundamentals

Metric	Value
Market capitalization	€152.74m
Number of shares	41.6m
52-week high/low	€4.88 - €1.86
Dividend yield	5.69%
Dividends TTM	€0.21
Beta	1.28
P/E ratio	0.97
PEG ratio	0.00
P/B ratio	0.53
P/S ratio	0.00

Company profile

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.